| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 7.96▲ | 8.01▼ | 8.03▼ | 8.31▼ | 7.28▲ |
| MA10 | 8.03▼ | 8.11▼ | 8.18▼ | 8.02▲ | 7.12▲ |
| MA20 | 8.13▼ | 8.27▼ | 8.26▼ | 7.42▲ | 8.27▼ |
| MA50 | 8.30▼ | 8.19▼ | 7.98▲ | 7.20▲ | 8.12▲ |
| MA100 | 8.18▼ | 7.76▲ | 7.45▲ | 8.09▲ | N/A |
| MA200 | 7.73▲ | 7.09▲ | 6.81▲ | 8.17▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.009▼ | -0.054▼ | -0.072▼ | 0.131▲ | -0.082▼ |
| RSI | 43.202▼ | 41.639▼ | 44.982▼ | 58.787▲ | 50.793▲ |
| STOCH | 22.878 | 14.945▼ | 12.240▼ | 78.236 | 35.175 |
| WILL %R | -64.474 | -75.000▼ | -79.545▼ | -36.336 | -59.356 |
| CCI | -45.362 | -98.714 | -120.568▼ | 38.609 | 9.208 |
|
Friday, August 15, 2025 03:57 AM
NasdaqGM:ACTU 1 Year Share Price vs Fair Value Explore Actuate Therapeutics's Fair Values from the Community and ...
|
|
Tuesday, July 29, 2025 04:35 PM
Actuate Therapeutics (NASDAQ:ACTU) is a keen biotech to look at because it has been making significant progress in targeting a hard-to-treat group of advanced cancer patients. This would be the ...
|
|
Thursday, July 17, 2025 05:51 AM
CHICAGO and FORT WORTH, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 7.98 | 8.2177 | 7.76 | 8.12 | 43,314 |
| 14/08/25 | 8.9904 | 8.9904 | 8.21 | 8.22 | 26,380 |
| 13/08/25 | 8.62 | 8.70 | 8.36 | 8.53 | 173,059 |
| 12/08/25 | 8.11 | 8.67 | 7.789 | 8.67 | 67,924 |
| 11/08/25 | 7.95 | 8.28 | 7.76 | 8.01 | 24,165 |
| 08/08/25 | 8.055 | 8.331 | 7.76 | 8.02 | 115,900 |
| 07/08/25 | 8.20 | 8.41 | 7.76 | 8.07 | 39,700 |
| 06/08/25 | 7.7498 | 8.4297 | 7.50 | 8.17 | 172,704 |
| 05/08/25 | 7.04 | 7.33 | 6.808 | 7.31 | 43,600 |
| 04/08/25 | 7.26 | 7.32 | 6.925 | 7.07 | 17,400 |
|
|
||||
|
|
||||
|
|